TransThera Sciences

TransThera Sciences includes its drug **YOCHANRA (tinengotinib)**, a self-developed multi-target kinase inhibitor, in the **Chinese Society of Clinical Oncology (CSCO) guidelines** for diagnosing and treating biliary tract cancers. The guidelines recommend tinengotinib as a **Class II, 2A treatment** for advanced-stage biliary tract cancers. The drug previously received **conditional marketing approval** from regulators.

Sep 2026MarketScreenerNews article

TransThera Sciences dispenses its first prescription of **YOCHANRA (tinengotinib)**, a targeted therapy for advanced cholangiocarcinoma, in China. The drug, approved as the world’s first for post-FGFR-inhibitor cases, was prescribed by Professor Zhou Jun at Peking University Cancer Hospital to a patient with FGFR2 fusion/rearrangement tumors. YOCHANRA represents TransThera’s first independently developed Class 1 innovative drug.

Sep 2026Insight, China's Pharmaceutical IndustryNews article

Transthera Sciences secures Chinese regulatory approval for **Yochanra (tinengotinib)**, a treatment for **FGFR2-positive cholangiocarcinoma** in patients whose disease has progressed after prior FGFR inhibitor therapy. The drug represents a potential new option for patients who have run out of targeted treatment alternatives in this molecularly defined cancer subtype. Approval follows prior advancements in precision oncology for cholangiocarcinoma.

Aug 2026bioworld.comNews article

China approves **TransThera Sciences'** multikinase inhibitor **Yochanra** as the first drug globally to address resistance to **FGFR inhibitors** in bile duct cancer. The approval targets patients whose tumors no longer respond to existing targeted therapies. Regulatory clearance follows clinical validation of Yochanra’s efficacy in overcoming treatment resistance.

Aug 2026pharmaphorumNews article